APA (7th ed.) Citation

Y, S., H, Y., M, S., H, T., N, A., T, S., . . . A, T. (2026). Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial. Targeted oncology. https://doi.org/10.1007/s11523-026-01223-2

Chicago Style (17th ed.) Citation

Y, Sunakawa, et al. "Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial." Targeted Oncology 2026. https://doi.org/10.1007/s11523-026-01223-2.

MLA (9th ed.) Citation

Y, Sunakawa, et al. "Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial." Targeted Oncology, 2026, https://doi.org/10.1007/s11523-026-01223-2.